Iron Sulfate, 59Fe

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Iron sulfate, 59Fe: instructions for use and reviews

1. Release form and composition
2. Pharmacological properties
3. Indications for use
4. Contraindications
5. Method of application and dosage
6. Side effects
7. Overdose
8. Special instructions
9. Application during pregnancy and lactation
10. Use in childhood
11. Drug interactions
12. Analogs
13. Terms and conditions of storage
14. Terms of dispensing from pharmacies
15. Reviews
16. Price in pharmacies

Latin name: Ferric sulfate, 59Fe

ATX code: V09XX

Active ingredient: Iron-59

Manufacturer: MEDRADIOPREPARAT PLANT (Russia)

Description and photo updated: 2017-14-11

Iron sulfate, 59Fe is a radiopharmaceutical diagnostic product.

Release form and composition

Iron sulfate, 59Fe is available in the form of capsules: gelatinous solid, size 1; body - white, lid - orange; the capsules contain white powder (10 or 15 pcs. in hermetically sealed vials, 1 vial in a transport packaging set for radioactive substances).

Composition of Iron sulfate, 59Fe (1 capsule):

active substance: iron-59 - 30 kBq;
auxiliary component: dextrose - 300 mg;
shell: titanium dioxide - 2.5%; crimson dye - 1.36%; iron oxide (III) - 0.85%; gelatin - up to 100%.

Pharmacological properties

Pharmacodynamics

Iron-59 after oral administration on an empty stomach dissolves in the stomach.

The principle of action of the drug is based on the distribution of iron with blood flow and its selective accumulation, in particular in the cells of tumor tissues.

Pharmacokinetics

After 3 hours, the main amount of radioactive iron is found in the gastrointestinal tract (of the administered amount: large intestine - 19%, small intestine - 33%, stomach - 36%).

The radioactivity caused by the active substance in the blood and kidneys after 3 hours is slightly higher than the background, in the spleen, bone marrow and muscle tissue it is within normal limits. 5 hours after taking the drug, radioactivity in the small intestine and stomach decreases to 12% and 14%, respectively, in the large intestine it increases to 33%. After 24–48 hours, 95% of the administered dose is excreted from the body.

The level of accumulation of iron-59 in the tumor varies from 0.7% to 0.9%, it remains unchanged for 48 hours.

Indications for use

Iron sulfate, 59Fe is recommended for use as a screening method for detecting breast pathologies.

Contraindications

violations of the act of swallowing;
pregnancy and the period of breastfeeding;
age up to 18 years;
individual intolerance to the components of the drug.

Instructions for use of Iron sulfate, 59Fe: method and dosage

The drug is taken orally.

24 hours before the examination, the patient should take 1 capsule with an activity of 30 kBq on an empty stomach. Measurement of iron-59 radiation is carried out on a two-channel scintillation gamma-spectrometer simultaneously from both mammary glands. The procedure should be performed 2 times: before the administration of the drug (own background) and 24–36 hours after the administration.

The measurement duration varies from 5 to 10 minutes.

The level of accumulation of iron-59 in each of the mammary glands (minus the background data) is recorded on the spectrograms. If the accumulation of RP in one of the mammary glands exceeds 1.4 times or more in comparison with the contralateral, the results of the study are recognized as positive.

The radiation loads on the tissues and organs of the patient are different and are assessed by the doctor.

Side effects

When using the drug for diagnostics, the development of any adverse reactions was not recorded.

Overdose

Due to the careful monitoring of the injected activity carried out in a specialized hospital, an overdose of the drug is unlikely.

special instructions

Work with the drug must be carried out in accordance with the following requirements:

"Basic Sanitary Rules for Ensuring Radiation Safety" (OSPORB - 99);
"Hygienic requirements for ensuring radiation safety during radionuclide diagnostics using radiopharmaceuticals" (MU 2.6.1. 1892-04);
"Radiation Safety Standards" (NRB-99).

Application during pregnancy and lactation

The period of pregnancy and lactation is a contraindication to the use of Iron sulfate, 59Fe.

Pediatric use

For pediatric patients (under 18 years of age), the drug is not prescribed.

Drug interactions

In the dosages used, no interaction with other drugs was observed.

Analogs

The group analogue of Iron sulfate, 59Fe is Ureacaps, 14C.

Terms and conditions of storage

Store in a cool place protected from light and moisture, observing OSPORB-99. Keep out of the reach of children.

The shelf life is 30 days.

Terms of dispensing from pharmacies

Released for hospitals.

Iron sulfate reviews, 59Fe

There are no reviews of Iron sulfate, 59Fe. The drug is intended for use in stationary conditions for diagnostic purposes.

Price for Iron sulfate, 59Fe in pharmacies

The price of Iron sulfate, 59Fe and its group analogue is unknown, since the preparations are not currently sold in pharmacies.

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!